Senior pharma executives expect industry 4.0 digital manufacturing technologies to produce significant cost savings and productivity improvements, according to a recent Bain & Company survey. The shift will help manufacturers reduce the complexity associated with smaller and more frequent drug launches as well as regulatory changes. In particular, pharma leaders are investing in smart factory management, next-generation operations planning and advanced analytics for quality management.
Frank Lesmeister is an expert vice president with Bain & Company’s Healthcare practice, and he is based in the firm’s Düsseldorf office.
How successful companies deliver the best return on digital operations.